hgp100 peptide vaccine

The hgp100 peptide vaccine is an investigational cancer immunotherapy designed to treat melanoma by targeting the human glycoprotein 100 (hgp100) antigen, also known as PMEL. It typically consists of synthetic peptides, such as the modified HLA-A*0201-restricted epitope gp100:209-217(210M), which are engineered to enhance binding affinity to MHC molecules and stimulate a robust cytotoxic T-lymphocyte (CTL) response. Often administered with adjuvants like Montanide ISA-51 and cytokines such as interleukin-2 (IL-2), the vaccine aims to induce immune-mediated destruction of melanoma cells expressing the gp100 differentiation antigen. Development has primarily been led by the National Cancer Institute (NCI) and academic centers, focusing on metastatic cutaneous and uveal melanoma.

Other names

gp100 vaccinegp-100 vaccinegp 100 vaccinehgp100 vaccinehgp-100 vaccinehgp 100 vaccinehuman glycoprotein 100 vaccinegp100 peptide vaccinegp-100 peptide vaccinegp 100 peptide vaccine